Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

The current therapeutic approach in Waldenström’s macroglobulinemia (WM) is being driven by insights in disease biology and genomic landscape. Bruton’s tyrosine kinase (BTK) plays a key role in signaling pathways for the survival of WM clone. BTK inhibition has changed the treatment landscape of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ntanasis-Stathopoulos, Ioannis, Gavriatopoulou, Maria, Fotiou, Despina, Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874350/
https://www.ncbi.nlm.nih.gov/pubmed/33613931
http://dx.doi.org/10.1177/2040620721989586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874350/
https://www.ncbi.nlm.nih.gov/pubmed/33613931
http://dx.doi.org/10.1177/2040620721989586

Ejemplares similares